St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.
Renal
TCT 2014: Is renal denervation dead or alive?
Medtronic’s renal denervation no better at 1 year, researchers say
Renal denervation isn’t dead, despite Medtronic trial’s failure
Kona Medical launches hypertension trial for non-invasive RDN device
Kona Medical said this week that it’s launched a clinical trial of the non-invasive renal denervation device for treating hypertension it calls Surround Sound.
Simple, not sexy: Twitter docs weigh in on the future of renal denervation
EuroPCR 2014: Looking for hope for renal denervation
Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.
EuroPCR 2014: St. Jude touts EnligHTN data amid renal denervation backlash
EuroPCR 2014: Docs say renal denervation ads are putting ‘marketing before science’
Attendees at this year’s EuroPCR conference in Paris cast a wary eye on medical device makers’ efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."
Hypertension: Docs turn on renal denervation | MassDevice.com On Call
MASSDEVICE ON CALL — A group of cardiologists is taking a hard stance against renal denervation, calling for medical device manufacturers to stop selling the technology as a treatment for hypertension.
ACC 2014: Conflicts in renal denervation, competition in valves
The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.